Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review
BackgroundOsimertinib, a third-generation tyrosine kinase inhibitor (TKI), has demonstrated significant efficacy in treating non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, EGFR-TKI-induced interstitial lung disease (ILD), a well-known adv...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Kniha |
| Vydáno: |
Frontiers Media S.A.,
2024-06-01T00:00:00Z.
|
| Témata: | |
| On-line přístup: | Connect to this object online. |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Jednotka 1 | Dostupné |